Ranbaxy Laboratories reports consolidated net loss of Rs 158.94 crore in Q4

05 Feb 2014 Evaluate

Ranbaxy Laboratories has reported results for fourth quarter ended December 31, 2013.

The company has reported a net loss at Rs 395.96 crore for the quarter as compared to net loss for Rs 616.09 crore for the same quarter in the previous year. Total income of the company decreased by 5.20% at Rs 1366.56 crore for quarter under review as compared to Rs 1441.52 crore for the quarter ended December 31, 2012.

For the year ended December 31, 2013, the company has posted net loss at Rs 1776.85 crore as compared to loss of Rs 162.33 crore in the previous year. Total income has decreased by 10.96% at Rs 5612.92 crore for year under review as compared to Rs 6303.54 crore for the period ended December 31, 2012.

On the consolidated basis, the group has reported a net loss after taxes and Minority Interest and Share of Profit of Associates of Rs 158.94 crore for the quarter as compared to net loss of Rs 492.44 crore for the same quarter in the previous year. However, total income from operations of the group has increased by 6.74% at Rs 2893.99 crore for quarter under review as compared to Rs 2711.21 crore for the quarter ended December 31, 2012.

For the year ended December 31, 2013, on the consolidated basis, a net loss after taxes and Minority Interest and Share of Profit of Associates of Rs 1011.59 crore as compared to net profit of Rs 922.76 crore for the same period in the previous year. Total income from operations has decreased by 13.31% at Rs 10801.66 crore for year under review as compared to Rs 12459.72 crore for the period ended December 31, 2012

Peers
Company Name CMP
Sun Pharma Inds. 1804.95
Dr. Reddys Lab 1275.05
Cipla 1520.55
Zydus Lifesciences 931.45
Lupin 2097.65
View more..
Register Now to get our Free Newsletter & much more!

© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×